Japanese Patients' and Physicians' Preferences for Anticoagulant Use in Atrial Fibrillation: Results from a

Ken Okumura1, Hiroshi Inoue2, Masahiro Yasaka3

  • 1Division of Cardiology Hirosaki University Graduate School of Medicine, Hirosaki-shi, Aomori, Japan.

Insights

Patients with atrial fibrillation (AF) prioritize stroke prevention over bleeding risk more than physicians do. Understanding these differing perspectives is crucial for effective anticoagulant therapy decisions.

Area of Science:

  • Cardiology
  • Medical Decision Making
  • Patient Preferences

Background:

  • Anticoagulants are vital for stroke prevention in atrial fibrillation (AF) but increase bleeding risks.
  • Physicians navigate complex benefit-risk tradeoffs when prescribing these therapies.
  • Limited data exists on patient and physician priorities regarding cardiovascular events versus bleeding.

Purpose of the Study:

  • To quantify patient and physician willingness to trade benefits and risks of anticoagulants.
  • To identify potential discrepancies in perceived benefits and risks between patients and physicians.
  • To inform clinical decision-making by understanding stakeholder preferences.

Main Methods:

  • A discrete-choice experiment was employed to elicit preferences from Japanese AF patients and physicians.
  • Random-parameters logit models analyzed importance weights for stroke, myocardial infarction, embolism, and bleeding risks.
  • Data was collected from 152 patients and 164 physicians.

Main Results:

  • Significant differences in preferences were observed between Japanese patients and physicians.
  • Patients valued disabling stroke prevention 16 times more than non-major bleeding and 2.6 times more than major extra-cranial bleeding.
  • Physicians prioritized stroke risk 2.7 times over non-major bleeding and equally with major bleeding.

Conclusions:

  • Japanese patients exhibit a higher tolerance for bleeding risk to achieve stroke prevention compared to Japanese physicians.
  • These findings underscore the critical role of physician-patient communication in shared decision-making for stroke prevention.
  • Tailoring anticoagulant therapy discussions to individual patient priorities can optimize treatment outcomes.

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
749
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
12
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12